Display options
Cite
Tang HC, Chen YC. Identification of tyrosinase inhibitors from traditional Chinese medicines for the management of hyperpigmentation. Springerplus. 2015;4:184doi: 10.1186/s40064-015-0956-0.
Tang, H. C., & Chen, Y. C. (2015). Identification of tyrosinase inhibitors from traditional Chinese medicines for the management of hyperpigmentation. SpringerPlus, 4184. https://doi.org/10.1186/s40064-015-0956-0
Tang, Hsin-Chieh, and Chen, Yu-Chian. "Identification of tyrosinase inhibitors from traditional Chinese medicines for the management of hyperpigmentation." SpringerPlus vol. 4 (2015): 184. doi: https://doi.org/10.1186/s40064-015-0956-0
Tang HC, Chen YC. Identification of tyrosinase inhibitors from traditional Chinese medicines for the management of hyperpigmentation. Springerplus. 2015 Apr 17;4:184. doi: 10.1186/s40064-015-0956-0. eCollection 2015. PMID: 25932370; PMCID: PMC4411401.
Copy Download .nbib Format: NLM
Share it on

Springerplus. 2015 Apr 17;4:184. doi: 10.1186/s40064-015-0956-0. eCollection 2015.

Identification of tyrosinase inhibitors from traditional Chinese medicines for the management of hyperpigmentation.

SpringerPlus

Hsin-Chieh Tang, Yu-Chian Chen

Affiliations

  1. Department of Biomedical Informatics, Asia University, Taichung, 41354 Taiwan.
  2. Department of Biomedical Informatics, Asia University, Taichung, 41354 Taiwan ; Human Genetic Center, Department of Medical Research, China Medical University Hospital, Taichung, 40402 Taiwan ; Research Center for Chinese Medicine &Acupuncture, China Medical University, Taichung, 40402 Taiwan.

PMID: 25932370 PMCID: PMC4411401 DOI: 10.1186/s40064-015-0956-0

Abstract

The inhibition of tyrosinase is the most effective method to decrease melanin synthesis during the process of pigmentation. We aimed to find compounds from traditional Chinese medicines (TCM) that are more effective than the most commonly used tyrosinase inhibitor, arbutin. First, we employed homology modeling to construct a tyrosinase-modeled structure, and structure-based virtual screening to screen from 61,000 TCM compounds. We also adopted the following quantitative structure-activity relationship (QSAR) models for ligand-based validation: support vector machine, multiple linear regression, and Bayesian network. Molecular dynamics (MD) simulation was used to confirm the stability of ligand binding. We found that merresectine C might more effectively bind and inhibit the activity of tyrosinase than arbutin. This study provides useful evidence for the potential development of a novel non-toxic bleaching or whitening ingredient.

Keywords: Ligand-based; Molecular dynamics (MD) simulation; Quantitative structure-activity relationship (QSAR); Structure-based; Traditional Chinese medicine (TCM); Tyrosinase inhibitor

References

  1. Bioorg Med Chem. 2012 Sep 15;20(18):5649-57 - PubMed
  2. J Invest Dermatol. 1989 Aug;93(2):201-9 - PubMed
  3. Nature. 2007 Feb 22;445(7130):843-50 - PubMed
  4. Nature. 2008 Aug 28;454(7208):1142-6 - PubMed
  5. N Engl J Med. 1990 Jun 14;322(24):1724-8 - PubMed
  6. Nat New Biol. 1971 Apr 7;230(14):187 - PubMed
  7. Science. 1955 Jun 24;121(3156):893-4 - PubMed
  8. Science. 1982 Aug 6;217(4559):545-7 - PubMed
  9. Lancet. 1994 Oct 15;344(8929):1049-52 - PubMed
  10. Basic Clin Pharmacol Toxicol. 2011 Nov;109 (5):372-80 - PubMed
  11. Nature. 2010 Jun 3;465(7298):577-83 - PubMed
  12. Science. 1969 May 16;164(3881):838-9 - PubMed
  13. J Toxicol Sci. 2009 Jun;34(3):305-13 - PubMed
  14. Food Chem Toxicol. 2011 Feb;49(2):471-6 - PubMed
  15. Nat New Biol. 1972 Feb 2;235(57):147-9 - PubMed
  16. N Engl J Med. 1993 May 20;328(20):1438-43 - PubMed
  17. Science. 1979 Feb 2;203(4379):410-5 - PubMed
  18. Science. 1967 Jan 13;155(3759):198-200 - PubMed
  19. PLoS Comput Biol. 2012;8(10):e1002708 - PubMed
  20. J Investig Dermatol Symp Proc. 2008 Apr;13(1):10-4 - PubMed
  21. Science. 1972 Feb 11;175(4022):642-4 - PubMed
  22. Nature. 1965 Jan 16;205:291-2 - PubMed
  23. Clin Toxicol (Phila). 2011 Dec;49(10):886-91 - PubMed
  24. Lancet. 1984 Jan 21;1(8369):159 - PubMed
  25. N Engl J Med. 2006 Nov 16;355(20):e23 - PubMed
  26. Lancet. 2003 Mar 22;361(9362):1056 - PubMed
  27. N Engl J Med. 2010 Dec 9;363(24):e36 - PubMed
  28. J Invest Dermatol. 2013 Jan;133(1):11-3 - PubMed
  29. Science. 2005 Jun 24;308(5730):1890-2 - PubMed
  30. Cell. 2013 Nov 21;155(5):1022-33 - PubMed
  31. Trends Pharmacol Sci. 2002 Mar;23(3):136-9 - PubMed
  32. Lancet. 1995 Dec 23-30;346(8991-8992):1713 - PubMed
  33. N Engl J Med. 2004 Apr 8;350(15):1526-34 - PubMed
  34. J Invest Dermatol. 2012 Dec;132(12):2678-80 - PubMed
  35. Eur J Med Chem. 2009 Aug;44(8):3195-200 - PubMed
  36. Arch Toxicol. 2012 Nov;86(11):1773-81 - PubMed
  37. Science. 1994 Mar 11;263(5152):1444-6 - PubMed
  38. J Invest Dermatol. 2012 Nov;132(11):2622-31 - PubMed
  39. PLoS One. 2011 Jan 06;6(1):e15939 - PubMed
  40. N Engl J Med. 1977 Sep 22;297(12):634-7 - PubMed
  41. J Invest Dermatol. 2012 Jan;132(1):13-5 - PubMed
  42. Science. 1950 Aug 25;112(2904):223-5 - PubMed
  43. Lancet. 1977 Apr 9;1(8015):811 - PubMed
  44. Science. 1982 Sep 17;217(4565):1163-5 - PubMed
  45. N Engl J Med. 2010 Sep 2;363(10):901-3 - PubMed

Publication Types